Evidence map›Paper›PMID 37487115›Full record

ArticleACS chemical neuroscience2023

Characterization of Uranyl (UO

Elina Berntsson, Faraz Vosough, Andra Noormägi, Kärt Padari, Fanny Asplund, Maciej Gielnik, Suman Paul, Jüri Jarvet, Vello Tõugu, Per M Roos and 6 more

Open access · hybridAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Experimental methods for studying amyloid cross-interactions.Protein science : a publication of the Protein Society · 2025
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Elina BerntssonChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.ORCID 0000-0002-7544-092X
Faraz VosoughChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.
Andra NoormägiDepartment of Chemistry and Biotechnology, Tallinn University of Technology, 19086 Tallinn, Estonia.
Kärt PadariInstitute of Molecular and Cell Biology, University of Tartu, 50090 Tartu, Estonia.
Fanny AsplundChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.
Maciej GielnikDepartment of Molecular Biology and Genetics, Aarhus University, 8000 Aarhus, Denmark.ORCID 0000-0002-1990-2800
Suman PaulChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.
Jüri JarvetChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.ORCID 0000-0002-7863-1887
Vello TõuguDepartment of Chemistry and Biotechnology, Tallinn University of Technology, 19086 Tallinn, Estonia.
Per M RoosInstitute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.
Maciej KozakDepartment of Biomedical Physics, Institute of Physics, Faculty of Physics, Adam Mickiewicz University, 61-712 Poznań, Poland.ORCID 0000-0003-3312-6518
Astrid GräslundChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.
Andreas BarthChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.ORCID 0000-0001-5784-7673
Margus PoogaInstitute of Technology, University of Tartu, 50090 Tartu, Estonia.
Peep PalumaaDepartment of Chemistry and Biotechnology, Tallinn University of Technology, 19086 Tallinn, Estonia.ORCID 0000-0002-3505-3466
Sebastian K T S WärmländerChemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.ORCID 0000-0003-3917-1838
Stockholm University · SETallinn University of Technology · EEUniversity of Tartu · EEAarhus University · DKJagiellonian University · PLKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uranium (U) is naturally present in ambient air, water, and soil, and depleted uranium (DU) is released into the environment via industrial and military activities. While the radiological damage from U is rather well understood, less is known about the chemical damage mechanisms, which dominate in DU. Heavy metal exposure is associated with numerous health conditions, including Alzheimer's disease (AD), the most prevalent age-related cause of dementia. The pathological hallmark of AD is the deposition of amyloid plaques, consisting mainly of amyloid-β (Aβ) peptides aggregated into amyloid fibrils in the brain. However, the toxic species in AD are likely oligomeric Aβ aggregates. Exposure to heavy metals such as Cd, Hg, Mn, and Pb is known to increase Aβ production, and these metals bind to Aβ peptides and modulate their aggregation. The possible effects of U in AD pathology have been sparsely studied. Here, we use biophysical techniques to study in vitro interactions between Aβ peptides and uranyl ions, UO

Indexed as

Alzheimer DiseaseUraniumAmyloidAmyloid beta-PeptidesAnimalsIonsAmyloidAmyloid beta-PeptidesIonsUraniumAlzheimer’s diseaseamyloid aggregationheavy metal toxicitymetal−protein bindingneurodegeneration

Identifiers

PMID37487115
PMCPMC10401651
OpenAlexW4385221960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.